reduce insulin dose when starting glp-1 receptor agonist Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Item - To reduce or
Description
Dedicated cardiovascular outcomes trials for tirzepatide are ongoing
Overall, our meta-analysis underscores the value of GLP-1RAs as a multifaceted therapeutic option, particularly in PCOS patients with obesity and IR

There may be difficulties in having to refrigerate the injectable versions

Rowbottom, L., Stinson, J., McDonald, R., Emmenegger, U., Cheng, S., Lowe, J., Giotis, A., Cheon, P., Chow, R., Pasetka, M., et al
